As a result, scholars validated the tumor suppressive effect of IL-15 on PDX models, and they demonstrated that the replacement of IL-2 with IL-15 was associated with significant tumor regression in vivo, supporting clinical trials of IL-15 for pediatric neuroblastoma (77). This evidence concerns the gene IL15 and neuroblastoma.